Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies
Chronic Lymphocytic Leukemia|Non-Hodgkin's Lymphoma
DRUG: Ublituximab + TGR-1202|DRUG: Ublituximab + TGR-1202 + ibrutinib|DRUG: Ublituximab + TGR-1202 + bendamustine
Maximum Tolerated Dose acceptable for participants, To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities, 28 days (1 cycle of therapy)
Overall Response Rate, To assess the overall response rate (ORR) in patients with hematologic malignancies treated with Ublituximab in combination with TGR-1202, Up to 1 year
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies